ADCT
ADC Therapeutics SA
NYSE: ADCT · HEALTHCARE · BIOTECHNOLOGY
$3.78
+0.27% today
Updated 2026-04-29
Market cap
$480.78M
P/E ratio
—
P/S ratio
5.91x
EPS (TTM)
$-1.12
Dividend yield
—
52W range
$1 – $5
Volume
0.9M
ADC Therapeutics SA (ADCT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $155.08M | $271.95M | $150.56M | $137.68M | $513.69M | $617.97M | $490.86M | $354.78M | $321.98M |
| Cash & equivalents | $143.67M | $262.75M | $138.81M | $115.55M | $439.19M | $466.54M | $326.44M | $278.60M | $250.87M |
| Current assets | $151.25M | $265.17M | $142.08M | $122.61M | $450.45M | $525.18M | $434.98M | $336.29M | $307.39M |
| Total liabilities | $14.18M | $22.78M | $24.32M | $26.53M | $178.19M | $451.88M | $411.41M | $503.03M | $524.62M |
| Current liabilities | $9.67M | $20.55M | $22.35M | $19.94M | $40.44M | $73.94M | $81.94M | $67.67M | $80.47M |
| Long-term debt | — | — | — | — | $107.98M | $125.10M | $97.24M | $112.73M | $113.63M |
| Shareholder equity | $140.89M | $249.17M | $126.24M | $111.16M | $335.50M | $166.09M | $79.45M | $-148.25M | $-202.64M |
| Retained earnings | $-119.13M | $-208.99M | $-332.08M | $-448.57M | $-694.86M | $-924.88M | $-1.10B | $-1.34B | $-1.49B |
| Accounts receivable | $5.91M | $1.93M | $372000.00 | $2.84M | $2.69M | $32.17M | $72.97M | $25.18M | $20.32M |
| Inventory | — | $293000.00 | $1.20M | $2.47M | $6.50M | $11.12M | $12.07M | $16.18M | $18.39M |
| Goodwill | — | — | — | — | — | — | — | — | — |